Modular Medical Inc. Receives IRB Approval for Feasibility Study of Next-Gen Pivot Insulin Delivery System
Reuters
Sep 15
Modular Medical Inc. Receives IRB Approval for Feasibility Study of Next-Gen Pivot Insulin Delivery System
Modular Medical Inc., a leader in innovative insulin delivery technology, announced that it has received Institutional Review Board (IRB) approval to conduct an in-house feasibility study of its next-generation Pivot insulin delivery system. The study will evaluate the usability and extended wear of the tubeless patch pump using sterile saline on adult participants over a period of up to 90 days. This approval is a crucial step toward refining the Pivot pump before its anticipated 510(k) submission to the FDA in October 2025. The study aims to identify challenges in prolonged wear, gather participant feedback, and support regulatory pathways to potentially unlock new markets. The Pivot pump is not yet cleared for sale by the FDA.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Modular Medical Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1073041) on September 15, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.